Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, . . . Arschang Valipour. (2020). Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. MDPI AG.
Chicago Style (17th ed.) CitationMaximilian J. Hochmair, et al. Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. MDPI AG, 2020.
MLA (9th ed.) CitationMaximilian J. Hochmair, et al. Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. MDPI AG, 2020.
Warning: These citations may not always be 100% accurate.